Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 55 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The firm is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. The firm is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in IgAN, which it refers to as ORIGIN 2b.